Minimally Invasive Benign Hysterectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01865929 |
Recruitment Status
: Unknown
Verified May 2013 by Celine Lönnerfors, Region Skane.
Recruitment status was: Recruiting
First Posted
: May 31, 2013
Last Update Posted
: May 31, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Menorrhagia Metrorrhagia Uterine Fibroids Cervical Dysplasia | Device: Robotic hysterectomy Procedure: Vaginal or laparoscopic hysterectomy | Not Applicable |
Laparoscopic surgery is advantageous compared to open surgery in terms of patient morbidity, shorter hospitalization and a more rapid return to daily activities. Robot-assisted laparoscopic surgery have facilitated a higher proportion of minimally invasive surgery first and foremost within gynecologic oncology.It is not clear whether or not this is true for less advanced surgery where a vaginal approach or a traditional laparoscopic approach is possible.
Robot-assisted surgery is associated with additional cost due to investment and more expensive surgical equipment. The study is performed to investigate whether or not performing hysterectomy for benign conditions with robotic surgery will be advantageous in terms of shorter operating time, less complications, less conversions to open surgery, and shorter hospital stay in comparison to other minimally invasive procedures such as vaginal hysterectomy and traditional laparoscopic hysterectomy.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Benign Hysterectomy; a Randomized Controlled Trial Comparing Robotic Hysterectomy With Vaginal Hysterectomy and Traditional Laparoscopic Hysterectomy |
Study Start Date : | January 2010 |
Estimated Primary Completion Date : | September 2014 |
Estimated Study Completion Date : | December 2015 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Robotic hysterectomy
Minimally invasive hysterectomy by robotic surgery
|
Procedure: Vaginal or laparoscopic hysterectomy
Benign hysterectomy performed by traditional minimal invasive procedures.
|
Active Comparator: Vaginal or laparoscopic hysterectomy
Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
|
Device: Robotic hysterectomy
Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
Other Name: da Vinci Surgical system, Intuitive Surgical Inc, CA, USA
|
- Cost of surgery [ Time Frame: 4 months ]The cost of surgery includes the actual surgery (anaesthesia, OR-nurse, circulating nurse, doctors and use of the OR) as well as the length of the inpatient stay. The cost for conversions to open surgery, reoperations, readmissions, and any additional cost associated with additional procedures or medical interventions such as radiological examinations and blood transfusions. Based on the estimated cost of surgical material, use of the operating room and cost of anaesthesia each benign hysterectomy performed with robotic surgery would need to be 50 minutes shorter than other minimal invasive procedures to compensate for the additional cost.
- Patient outcome [ Time Frame: 4 months ]The number of patients in whom an intraoperative or postoperative complication occurs as well as the seriousness of the complication which occurs and what this entails for the patient in question. This includes conversions to open surgery as well as the need for reoperation and readmission.
- Social cost [ Time Frame: 4 months ]The length of postoperative sick leave and reasons for extending sick leave and cost thereof.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- indication for hysterectomy for benign disease or prophylactic surgery due to hereditary cancer
- size of uterus and vagina allows for retrieval by the vaginal route
- maximum uterine size equivalent to 16 weeks of pregnancy
- informed consent
Exclusion Criteria:
- malignant disease
- known extensive intra-abdominal adhesions
- anaesthesiological contraindications to laparoscopic surgery
- women with pacemaker or other implants where electrosurgery is to be avoided
- immunoincompetent women
- simultaneous need for prolapse surgery
- women with known defects of the hemostasis
- allergies towards metronidazole and doxycycline
- inability to understand patient information

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01865929
Contact: Jan Persson, MD, PhD | +4646171000 | jan.persson@med.lu.se | |
Contact: Celine Lönnerfors, MD | +4646171000 | celine.lonnerfors@med.lu.se |
Sweden | |
Department of Obstetrics and Gynecology, Skane University Hospital | Recruiting |
Lund, Sweden, 221 85 | |
Contact: Jan Persson, MD, PhD jan.persson@med.lu.se | |
Principal Investigator: Jan Persson, MD, PhD | |
Sub-Investigator: Celine Lönnerfors, MD |
Study Director: | Jan Persson, MD, PhD | Department of Obstetrics and Gynecology, Skane University Hospital, Lund |
Responsible Party: | Celine Lönnerfors, Medical Doctor, Region Skane |
ClinicalTrials.gov Identifier: | NCT01865929 History of Changes |
Other Study ID Numbers: |
LundKK |
First Posted: | May 31, 2013 Key Record Dates |
Last Update Posted: | May 31, 2013 |
Last Verified: | May 2013 |
Additional relevant MeSH terms:
Leiomyoma Myofibroma Menorrhagia Uterine Cervical Dysplasia Cervical Intraepithelial Neoplasia Metrorrhagia Neoplasms, Muscle Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Neoplasms, Connective Tissue Connective Tissue Diseases |
Uterine Hemorrhage Uterine Diseases Genital Diseases, Female Menstruation Disturbances Pathologic Processes Precancerous Conditions Uterine Cervical Diseases Carcinoma in Situ Carcinoma Neoplasms, Glandular and Epithelial Hemorrhage |